Nifty
Sensex
:
:
11709.10
38969.80
-119.15 (-1.01%)
-382.87 (-0.97%)

Pharmaceuticals & Drugs

Rating :
61/99

BSE: 532531 | NSE: STAR

411.75
-10.50 (-2.49%)
21-May-2019 | 3:57PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  426.00
  •  436.95
  •  408.50
  •  422.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1780909
  •  7332.89
  •  551.40
  •  333.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,682.72
  • 11.35
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,899.36
  • 0.49%
  • 1.39

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 31.24%
  • 0.00%
  • 12.64%
  • FII
  • DII
  • Others
  • 1.1%
  • 22.40%
  • 32.62%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 20.01
  • 5.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 9.44
  • -1.62

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 67.81
  • 81.53

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.09
  • 22.35
  • 23.24

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.07
  • 3.64
  • 2.60

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.40
  • 20.45
  • 15.68

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
839.70
669.89
25.35%
794.50
748.79
6.10%
732.63
768.66
-4.69%
663.46
657.78
0.86%
Expenses
680.97
577.63
17.89%
667.41
617.83
8.02%
633.03
660.88
-4.21%
582.68
586.52
-0.65%
EBITDA
158.73
92.26
72.05%
127.09
130.96
-2.96%
99.60
107.78
-7.59%
80.78
71.26
13.36%
EBIDTM
18.90%
13.77%
16.00%
17.49%
13.59%
14.02%
12.18%
10.83%
Other Income
14.78
16.06
-7.97%
0.83
15.66
-94.70%
7.73
22.14
-65.09%
10.64
34.46
-69.12%
Interest
62.65
45.47
37.78%
50.09
49.77
0.64%
48.48
48.58
-0.21%
44.12
52.42
-15.83%
Depreciation
43.82
44.34
-1.17%
40.67
37.95
7.17%
44.49
37.25
19.44%
42.87
34.49
24.30%
PBT
76.01
-3.14
-
37.90
52.58
-27.92%
6.97
31.84
-78.11%
-0.51
15.45
-
Tax
11.05
-4.96
-
6.33
2.01
214.93%
1.61
5.42
-70.30%
-4.27
4.24
-
PAT
64.96
1.82
3,469.23%
31.57
50.57
-37.57%
5.36
26.42
-79.71%
3.76
11.21
-66.46%
PATM
7.74%
0.27%
3.97%
6.75%
0.73%
3.44%
0.57%
1.70%
EPS
5.31
63.65
-91.66%
32.77
9.56
242.78%
-1.34
0.96
-
-0.66
0.06
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Net Sales
3,030.29
3,338.63
3,826.22
2,862.19
1,195.85
1,340.96
961.76
2,550.04
1,695.84
1,304.77
1,020.33
Net Sales Growth
6.51%
-12.74%
33.68%
139.34%
-10.82%
39.43%
-62.28%
50.37%
29.97%
27.88%
 
Cost Of Goods Sold
1,466.01
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
1,264.39
805.65
700.90
524.20
Gross Profit
1,564.28
1,959.80
2,545.05
1,359.90
635.37
626.30
469.94
1,285.66
890.19
603.86
496.13
GP Margin
51.62%
58.70%
66.52%
47.51%
53.13%
46.71%
48.86%
50.42%
52.49%
46.28%
48.62%
Total Expenditure
2,564.09
2,987.89
3,309.30
2,481.62
967.00
1,117.54
861.18
2,059.36
1,369.22
1,117.84
950.87
Power & Fuel Cost
-
51.33
33.87
77.18
16.02
18.56
12.84
54.24
30.23
24.58
30.81
% Of Sales
-
1.54%
0.89%
2.70%
1.34%
1.38%
1.34%
2.13%
1.78%
1.88%
3.02%
Employee Cost
-
434.05
419.16
357.69
172.06
157.18
120.30
302.74
219.57
177.01
176.81
% Of Sales
-
13.00%
10.95%
12.50%
14.39%
11.72%
12.51%
11.87%
12.95%
13.57%
17.33%
Manufacturing Exp.
-
115.97
137.47
119.23
41.37
35.76
44.43
89.60
63.83
45.15
48.93
% Of Sales
-
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
3.51%
3.76%
3.46%
4.80%
General & Admin Exp.
-
194.38
172.63
198.71
86.25
66.37
58.16
182.12
159.16
86.87
80.59
% Of Sales
-
5.82%
4.51%
6.94%
7.21%
4.95%
6.05%
7.14%
9.39%
6.66%
7.90%
Selling & Distn. Exp.
-
208.85
161.12
129.57
61.37
66.67
39.94
116.07
88.02
73.40
71.81
% Of Sales
-
6.26%
4.21%
4.53%
5.13%
4.97%
4.15%
4.55%
5.19%
5.63%
7.04%
Miscellaneous Exp.
-
604.48
1,103.88
96.95
29.44
58.33
93.69
50.21
2.76
9.92
71.81
% Of Sales
-
18.11%
28.85%
3.39%
2.46%
4.35%
9.74%
1.97%
0.16%
0.76%
1.74%
EBITDA
466.20
350.74
516.92
380.57
228.85
223.42
100.58
490.68
326.62
186.93
69.46
EBITDA Margin
15.38%
10.51%
13.51%
13.30%
19.14%
16.66%
10.46%
19.24%
19.26%
14.33%
6.81%
Other Income
33.98
805.61
398.08
102.37
38.57
60.23
34.20
31.67
69.70
23.57
310.92
Interest
205.34
196.24
183.10
168.17
47.44
108.88
79.45
194.83
146.65
75.91
84.70
Depreciation
171.85
193.93
198.69
131.25
64.03
56.48
30.86
104.30
63.90
49.19
39.90
PBT
120.37
766.17
533.20
183.50
155.95
118.30
24.48
223.22
185.77
85.41
255.78
Tax
14.72
25.46
51.19
42.45
147.60
40.86
11.15
38.68
45.19
21.90
10.79
Tax Rate
12.23%
3.52%
10.30%
29.87%
99.35%
44.53%
1.54%
14.18%
24.25%
15.32%
9.39%
PAT
105.65
677.27
399.38
113.21
1.57
50.89
712.39
224.48
122.45
109.68
107.96
PAT before Minority Interest
100.39
697.14
445.58
99.68
0.98
50.89
713.44
234.01
141.18
121.04
104.08
Minority Interest
-5.26
-19.87
-46.20
13.53
0.59
0.00
-1.05
-9.53
-18.73
-11.36
3.88
PAT Margin
3.49%
20.29%
10.44%
3.96%
0.13%
3.80%
74.07%
8.80%
7.22%
8.41%
10.58%
PAT Growth
17.36%
69.58%
252.78%
7,110.83%
-96.91%
-92.86%
217.35%
83.32%
11.64%
1.59%
 
Unadjusted EPS
36.08
73.81
44.73
13.14
141.85
298.56
121.47
38.65
26.11
26.49
26.91

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Shareholder's Funds
2,454.56
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
1,371.48
1,282.78
831.07
415.41
Share Capital
89.50
89.42
89.35
59.62
59.57
58.80
58.38
57.74
89.38
89.21
Total Reserves
2,356.00
2,650.55
2,562.75
1,084.50
947.06
1,963.94
1,310.34
1,222.95
724.09
324.41
Non-Current Liabilities
1,908.40
2,048.67
2,760.03
285.79
306.42
900.59
1,132.57
2,012.89
1,459.17
1,306.42
Secured Loans
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
1,054.31
1,387.39
778.70
566.01
Unsecured Loans
0.23
14.84
12.13
17.16
1.24
0.00
0.00
622.45
678.17
736.00
Long Term Provisions
16.55
25.19
14.45
6.02
16.56
57.25
66.19
0.00
0.00
0.00
Current Liabilities
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
2,791.73
923.65
684.15
420.98
Trade Payables
712.07
774.09
775.40
234.41
262.31
463.08
585.04
419.85
445.23
335.64
Other Current Liabilities
129.98
819.08
347.93
502.47
127.27
651.65
1,369.80
305.00
64.64
24.28
Short Term Borrowings
944.39
1,393.96
700.48
203.03
224.56
599.89
684.65
0.00
0.00
0.00
Short Term Provisions
112.86
116.73
68.19
80.03
93.23
82.66
152.24
198.80
174.28
61.06
Total Liabilities
6,416.91
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
5,342.24
4,491.79
3,232.89
2,323.09
Net Block
2,735.01
2,909.03
2,678.68
701.36
554.53
3,016.72
3,187.64
2,328.27
1,856.59
969.52
Gross Block
3,028.73
3,186.12
2,825.43
1,080.55
907.33
3,514.29
3,644.82
2,626.71
2,080.70
1,189.65
Accumulated Depreciation
293.71
277.09
146.75
379.19
352.80
497.57
457.19
298.44
224.11
220.12
Non Current Assets
3,933.32
4,243.05
3,845.20
1,039.91
787.65
3,383.87
3,711.33
2,521.48
2,282.61
1,575.48
Capital Work in Progress
620.29
780.18
814.88
171.17
99.47
241.44
285.03
191.46
84.66
259.55
Non Current Investment
350.08
315.66
127.19
68.76
41.80
0.00
0.00
1.76
341.36
346.40
Long Term Loans & Adv.
199.64
222.56
201.83
96.72
90.40
118.75
229.99
0.00
0.00
0.00
Other Non Current Assets
28.30
15.62
22.62
1.91
1.45
6.96
8.67
0.00
0.00
0.00
Current Assets
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
1,625.27
1,960.40
950.29
747.52
Current Investments
311.48
1,279.54
1,213.76
561.29
401.24
0.06
0.00
0.00
0.00
0.00
Inventories
552.02
732.80
613.14
207.68
175.99
442.33
479.93
312.00
233.42
173.12
Sundry Debtors
882.18
995.91
1,032.97
389.96
364.00
483.23
538.44
383.78
420.27
337.51
Cash & Bank
303.33
329.48
311.59
146.88
231.15
165.74
259.73
339.45
91.20
56.95
Other Current Assets
434.59
209.70
245.90
69.18
136.26
319.58
347.17
925.17
205.40
179.94
Short Term Loans & Adv.
295.75
244.39
97.54
54.46
79.06
44.38
91.79
850.18
150.94
99.87
Net Current Assets
584.29
687.95
1,622.91
409.50
601.26
-386.35
-1,166.46
1,036.75
266.14
326.54
Total Assets
6,416.91
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98
5,342.23
4,491.80
3,232.90
2,323.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Cash From Operating Activity
187.07
288.14
73.25
83.40
-271.68
134.26
457.10
323.93
89.61
117.75
PBT
705.80
497.14
146.44
992.01
2,889.87
949.49
272.69
186.37
142.94
114.88
Adjustment
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
113.84
178.94
42.76
19.47
Changes in Working Capital
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
128.87
-2.09
-82.37
-6.80
Cash after chg. in Working capital
240.63
346.76
150.29
139.37
-145.81
223.00
515.40
363.23
103.33
127.54
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
-58.30
-39.29
-13.72
-9.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
-656.47
-941.00
-147.64
-218.93
Net Fixed Assets
709.54
-236.66
-535.93
-66.57
-119.10
-38.27
-18.46
-42.91
-26.86
-108.24
Net Investments
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
77.70
653.52
-578.46
-103.41
Others
-874.59
-306.76
-210.32
40.35
3,947.38
1,353.35
-715.71
-1,551.61
457.68
-7.28
Cash from Financing Activity
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
89.36
850.09
91.64
13.43
Net Cash Inflow / Outflow
-246.03
-60.33
792.35
-285.98
486.88
-49.23
-110.01
233.03
33.60
-87.75
Opening Cash & Equivalents
515.08
1,110.74
298.91
586.00
132.02
211.93
325.17
79.00
45.88
179.34
Closing Cash & Equivalent
256.16
515.08
1,110.74
298.42
586.00
132.02
212.27
325.17
78.78
45.88

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Book Value (Rs.)
273.24
306.41
296.83
191.91
168.99
343.78
233.49
220.07
190.06
90.98
ROA
9.65%
5.79%
2.03%
0.04%
1.48%
14.07%
4.76%
3.66%
4.36%
4.78%
ROE
26.89%
16.53%
5.25%
0.09%
3.36%
42.16%
17.77%
13.87%
21.45%
36.41%
ROCE
16.09%
10.75%
7.54%
10.92%
7.76%
21.08%
12.82%
11.96%
10.93%
12.20%
Fixed Asset Turnover
1.07
1.27
1.47
1.21
0.61
0.27
0.82
0.72
0.80
0.87
Receivable days
102.66
96.77
90.73
114.71
114.80
193.43
65.68
86.42
105.79
97.90
Inventory Days
70.23
64.20
52.34
58.37
83.78
174.61
56.40
58.62
56.75
66.94
Payable days
116.23
117.33
75.51
76.81
112.69
253.28
92.58
119.83
129.46
131.06
Cash Conversion Cycle
56.67
43.64
67.55
96.27
85.89
114.76
29.50
25.22
33.08
33.78
Total Debt/Equity
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
1.79
3.15
Interest Cover
4.68
3.71
1.85
4.13
1.84
10.12
2.40
2.27
2.88
2.36

News Update:


  • Strides Pharma Science reports 92% fall in Q4 consolidated net profit
    10th May 2019, 15:03 PM

    The company has reported a fall of 87.01% in its standalone net profit for the quarter ended March 31, 2019

    Read More
  • Strides Pharma Scien - Quarterly Results
    10th May 2019, 13:01 PM

    Read More
  • USFDA classifies Strides Pharma’s Puducherry facility as Official Action Initiated
    6th May 2019, 11:45 AM

    The company believes that the classification will not have an impact on the current supplies and revenues from the facility

    Read More
  • Strides Pharma gets EIR for Singapore facility
    2nd Apr 2019, 14:13 PM

    The inspection was concluded on February 1, 2019

    Read More
  • Strides Pharma Science’s arm, Pii get nod for Potassium Chloride Extended-Release Tablets
    2nd Apr 2019, 09:23 AM

    The product is an immediately dispersing extended-release oral dosage form of potassium chloride

    Read More
  • Strides Pharma Science gets nod for divestment of Australian Business
    28th Mar 2019, 11:43 AM

    The shareholders approved the resolutions with requisite majority

    Read More
  • Strides Pharma gets USFDA’s nod for greenfield oral dosage facility in Singapore
    27th Mar 2019, 14:08 PM

    The facility operating at its peak capacity will produce around 1.4 billion tablets and hard gelatin capsules

    Read More
  • Strides Pharma Science’s arm gets USFDA’s nod for Ethosuximide Softgel Capsules
    20th Feb 2019, 11:38 AM

    The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market

    Read More
  • Strides Pharma Science’s arm receives approval for Triamcinolone Acetonide Cream
    13th Feb 2019, 09:16 AM

    The product is a generic version of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc.

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.